[New therapeutic strategies in HER2-positive breast cancer]. / Nouvelles stratégies thérapeutiques dans les cancers du sein HER2-surexprimé.
Bull Cancer
; 2021 Jun 15.
Article
in Fr
| MEDLINE
| ID: mdl-34144793
ABSTRACT
Breast cancer with HER2-amplification accounts for 20% of breast cancers. The management of patients has dramatically changed with the advent of anti-HER2 treatment, especially the monoclonal antibodies since 2000 in the metastatic and (neo)-adjuvant setting, leading to an improvement of patient outcomes. If therapeutic arsenal has been gradually enhanced with the targeting of HER receptors family, resistances to these treatments are observed, hence the development of new therapeutic strategies. This review provides an updated look of novel therapeutic strategies in HER2-positive breast cancer, as well as future perspectives, both in the adjuvant and metastatic setting.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
Fr
Journal:
Bull Cancer
Year:
2021
Document type:
Article
Affiliation country:
Francia